PET/CT of cancer patients: Part 1, pancreatic neoplasms

American Journal of Roentgenology

Volumn 199, Issue 5, 2012, Pages 952-967

  Dibble, Elizabeth H ^a   Karantanis, Dimitrios ^b   Mercier, Gustavo ^a   Peller, Patrick J ^c   Kachnic, Lisa A ^a   Subramaniam, Rathan M ^a,d  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MAYO CLINIC   (United States)

^d DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

CT; MRI; Pancreatic cancer; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18; PENTETREOTIDE IN 111;

CANCER CLASSIFICATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PANCREAS ADENOCARCINOMA; PANCREAS CANCER; PANCREAS CYST; PANCREATIC NEUROENDOCRINE TUMOR; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SENSITIVITY AND SPECIFICITY; TREATMENT PLANNING; TREATMENT RESPONSE;

COST-BENEFIT ANALYSIS; DIAGNOSTIC IMAGING; FLUORODEOXYGLUCOSE F18; HUMANS; PANCREATIC NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; RADIOPHARMACEUTICALS;

EID: 84868031196     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.11.8182     Document Type: Review

References (86)

1. American Cancer Society Website. Cancer facts & figures. www.Cancer. Org/research/cancerfactsfigures/index. Accessed October 19, 2011
2. Gress TM, Michl P, Pauls S. Evidence-based diagnosis and staging of pancreatic cancer. Best Pract Res Clin Gastroenterol 2006;20:227-251
3. Balci NC, Semelka RC. Radiologic diagnosis and staging of pancreatic ductal adenocarcinoma. Eur J Radiol 2001;38:105-112 (Pubitemid 32396818)
4. Wong TZ, Paulson EK, Nelson RC, Patz EF Jr, Coleman RE. Practical approach to diagnostic CT combined with PET. AJR 2007;188:622-629
5. Subramaniam RM, Truong M, Peller P, Sakai O, Mercier G. Fluorodeoxyglucose-positron-emission tomography imaging of head and neck squamous cell cancer. AJNR 2010;31:598-604
6. Davison JM, Subramaniam RM, Surasi DS, Cooley T, Mercier G, Peller PJ. FDG PET/CT in patients with HIV. AJR 2011;197:284-294
7. Sacks A, Peller PJ, Surasi DS, Chatburn L, Mercier G, Subramaniam RM. Value of PET/CT in the management of primary hepatobiliary tumors, part 2. AJR 2011;197:366; [web]W260-W265
8. Sacks A, Peller PJ, Surasi DS, Chatburn L, Mercier G, Subramaniam RM. Value of PET/CT in the management of liver metastases, part 1. AJR 2011;197:365; [web]W256-W259
9. Wilcox BE, Subramaniam RM, Peller PJ, et al. Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma. Clin Lung Cancer 2009;10:244-248
10. 18F-fluoro-2-deoxy-d-glucose positron emission tomography and positron emission tomography/computed tomography imaging of malignant pleural mesothelioma. J Med Imaging Radiat Oncol 2009;53:160-169
11. Patel RR, Subramaniam RM, Mandrekar JN, Hammack JE, Lowe VJ, Jett JR. Occult malignancy in patients with suspected paraneoplastic neurologic syndromes: value of positron emission tomography in diagnosis. Mayo Clin Proc 2008;83:917-922
12. 18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients. Nucl Med Commun 2007;28:834-841 (Pubitemid 47494107)
13. 18F FDG PET/CT imaging. J Thorac Oncol 2007;2:569-570 (Pubitemid 47171813)
14. Klimstra DS, Pitman MB, Hruban RH. An algorithmic approach to the diagnosis of pancreatic neoplasms. Arch Pathol Lab Med 2009;133:454-464
15. Yao JC, Eisner MP, Leary C, et al. Populationbased study of islet cell carcinoma. Ann Surg Oncol 2007;14:3492-3500 (Pubitemid 350160130)
16. Vincent A, Herman J, Schulick R, Hruban RH, Goggins M. Pancreatic cancer. Lancet 2011;378:607-620
17. Pannala R, Leirness JB, Bamlet WR, Basu A, Petersen GM, Chari ST. Prevalence and clinical profile of pancreatic cancer-associated diabetes mellitus. Gastroenterology 2008;134:981-987 (Pubitemid 351451984)
18. Pelaez-Luna M, Takahashi N, Fletcher JG, Chari ST. Resectability of presymptomatic pancreatic cancer and its relationship to onset of diabetes: a retrospective review of CT scans and fasting glucose values prior to diagnosis. Am J Gastroenterol 2007;102:2157-2163 (Pubitemid 47493852)
19. Winter JM, Cameron JL, Lillemoe KD, et al. Periampullary and pancreatic incidentaloma: a single institution's experience with an increasingly common diagnosis. Ann Surg 2006;243:673-680; discussion, 680-683 (Pubitemid 44305587)
20. Lahat G, Ben Haim M, Nachmany I, et al. Pancreatic incidentalomas: high rate of potentially malignant tumors. J Am Coll Surg 2009;209:313-319
21. Aboyans V, Lacroix P, Cornu E, et al. Paraneoplastic arterial thrombosis: two case reports [in French]. Arch Mal Coeur Vaiss 1996;89:1297-1300 (Pubitemid 26348028)
22. Dumitrascu DL, Suciu O, Grad C, Gheban D. Thrombotic complications of pancreatic cancer: classical knowledge revisited. Dig Dis 2010;28:350-354
23. Varki A. Trousseau's syndrome: multiple definitions and multiple mechanisms. Blood 2007;110:1723-1729 (Pubitemid 47443881)
24. Marsh R de W, Hagler KT, Carag HR, Flowers FP. Pancreatic panniculitis. Eur J Surg Oncol 2005;31:1213-1215 (Pubitemid 41819210)
25. Kuempers P, Kohler L, Pertschy S, Kruger M, Zeidler H, Freise J. Unilateral fasciitis of the lower leg: a paraneoplastic manifestation of an occult pancreatic tumor. J Clin Rheumatol 2006;12:139-141 (Pubitemid 44314975)
26. Levin J, Camisa C. Unresponsive eczematous dermatitis: a case of pancreatic cancer masquerading as cutaneous T cell lymphoma. Cutis 1999;64:113-114
27. Cox NH, Ramsay B, Dobson C, Comaish JS. Woody hands in a patient with pancreatic carcinoma: a variant of cancer-associated fasciitis-panniculitis syndrome. Br J Dermatol 1996;135:995-998 (Pubitemid 26397935)
28. Ulla JL, Garcia-Doval I, Posada C, et al. Plantar keratoderma as a presenting sign of pancreatic adenocarcinoma. J Clin Ultrasound 2008;36:108-109
29. Nissen NN, Kim AS, Yu R, et al. Pancreatic neuroendocrine tumors: presentation, management, and outcomes. Am Surg 2009;75:1025-1029
30. Kulke MH, Bendell J, Kvols L, Picus J, Pommier R, Yao J. Evolving diagnostic and treatment strategies for pancreatic neuroendocrine tumors. J Hematol Oncol 2011;14:29
31. Zhu L, Domenico DR, Howard JM. Metastatic pancreatic neuroendocrine carcinoma causing Cushing's syndrome. Int J Pancreatol 1996;19:205-208
32. Kondo T, Matsuyama R, Ashihara H, et al. A case of ectopic adrenocorticotropic hormone-producing pancreatic neuroendocrine tumor with multiple liver metastases. Endocr J 2010;57:229-236
33. Garcia-Carbonero R, Capdevila J, Crespo-Herrero G, et al. Incidence, patterns of care and prognostic factors for outcome of gastroenteropancreatic neuroendocrine tumors (GEP-NETs): results from the National Cancer Registry of Spain (RGETNE). Ann Oncol 2010;21:1794-1803
34. Soga J. Carcinoids of the pancreas: an analysis of 156 cases. Cancer 2005;104:1180-1187 (Pubitemid 41278952)
35. Rasnake MS, Glanton C, Ornstein D, Osswald M, Garrison M. Hypercalcemia mediated by parathyroid hormone-related protein as an early manifestation of pancreatic adenocarcinoma metastasis: a case report. Am J Clin Oncol 2001;24:416-417 (Pubitemid 32730744)
36. National Comprehensive Cancer Network Website. NCCN guidelines version 1.2012: pancreatic adenocarcinoma. www.nccn.org/professionals/physician-gls/pdf/ pancreatic.pdf. Accessed October 19, 2011
37. National Comprehensive Cancer Network Website. NCCN guidelines version 1.2011: neuroendocrine tumors. www.nccn.org/professionals/physician-gls/pdf/ neuroendocrine.pdf. Accessed October 19, 2011
38. American College of Radiology Website. ACR appropriateness criteria: clinical condition-palpable abdominal mass. www.acr.org. Accessed October 28, 2011
39. American College of Radiology Website. ACR appropriateness criteria: clinical condition-painless jaundice. www.acr.org. Accessed October 28, 2011
40. Van Kouwen MC, Jansen JB, Van Goor H, De Castro S, Oyen WJ, Drenth JP. FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis. Eur J Nucl Med Mol Imaging 2005;32:399-404 (Pubitemid 40591171)
41. Gambhir SS, Czernin J, Schwimmer J, Silverman D H S, Coleman RE, Phelps ME. A tabulated summary of the FDG PET literature. J Nucl Med 2001;42 (5 suppl):1S-93S (Pubitemid 32423895)
42. Lemke AJ, Niehues SM, Hosten N, et al. Retrospective digital image fusion of multidetector CT and F-18-FDG PET: clinical value in pancreatic lesions-a prospective study with 104 patients. J Nucl Med 2004;45:1279-1286 (Pubitemid 47618523)
43. Kim JH, Park SH, Yu ES, et al. Visually isoattenuating pancreatic adenocarcinoma at dynamicenhanced CT: frequency, clinical and pathologic characteristics, and diagnosis at imaging examinations. Radiology 2010;257:87-96
44. 18F-FDG PET/CT for differentiation of autoimmune pancreatitis with atypical pancreatic imaging findings from pancreatic cancer. AJR 2009;193:343-348
45. Kamisawa T, Takum K, Anjiki H, et al. FDGPET/CT findings of autoimmune pancreatitis. Hepatogastroenterology 2010;57:447-450
46. Takanami K, Hiraide T, Tsuda M, et al. Additional value of FDG PET/CT to contrast-enhanced CT in the differentiation between benign and malignant intraductal papillary mucinous neoplasms of the pancreas with mural nodules. Ann Nucl Med 2011;25:501-510
47. 18F-FDG PET, combined FDG-PET/CT and EUS in diagnosing primary pancreatic carcinoma: a meta-analysis. Eur J Radiol 2011;78:142-150
48. Heinrich S, Goerres GW, Schafer M, et al. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 2005;242:235-243 (Pubitemid 41033440)
49. Schick V, Franzius C, Beyna T, et al. Diagnostic impact of F-18-FDG PET-CT evaluating solid pancreatic lesions versus endosonography, endoscopic retrograde cholangio-pancreatography with intraductal ultrasonography and abdominal ultrasound. Eur J Nucl Med Mol Imaging 2008;35:1775-1785
50. Kauhanen SP, Komar G, Seppanen MP, et al. A prospective diagnostic accuracy study of (18) Ffluorodeoxyglucose positron emission tomogra phy/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer. Ann Surg 2009;250:957-963
51. 18F-fluorodeoxyglucose positron emission tomography/computed tomography in detection and presurgical assessment of pancreatic cancer: a prospective study. J Gastroenterol Hepatol 2011;26:657-662
52. Romagnuolo J, Bardou M, Rahme E, Joseph L, Reinhold C, Barkun AN. Magnetic resonance cholangiopancreatography: a meta-analysis of test performance in suspected biliary disease. Ann Intern Med 2003;139:547-557
53. Muhi A, Ichikawa T, Motosugi U, et al. High-bvalue diffusion-weighted MR imaging of hepatocellular lesions: estimation of grade of malignancy of hepatocellular carcinoma. J Magn Reson Imaging 2009;30:1005-1011
54. Klauss M, Lemke A, Grünberg K, et al. Intravoxel incoherent motion MRI for the differentiation between mass forming chronic pancreatitis and pancreatic carcinoma. Invest Radiol 2011;46:57-63
55. Macari M, Finn ME, Bennett GL, et al. Differentiating pancreatic cystic neoplasms from pancreatic pseudocysts at MR imaging: value of perceived internal debris. Radiology 2009;251:77-84
56. Tanaka M, Chari S, Adsay V, et al. International consensus guidelines for management of intraductal papillary mucinous neoplasms and mucinous cystic neoplasms of the pancreas. Pancreatology 2006;6:17-32
57. Simeone DM. SSAT/AGA/ASGE state of the art conference on cystic neoplasms of the pancreas. J Gastrointest Surg 2008;12:1475-1477
58. Berland LL. The American College of Radiology strategy for managing incidental findings on abdominal computed tomography. Radiol Clin North Am 2011;49:237-243
59. Macari M, Megibow AJ. Focal cystic pancreatic lesions: variability in radiologists' recommendations for follow-up imaging. Radiology 2011;259:20-23
60. Di Muzio N, Broggi S, Passoni P, et al. PET/CT guided helical tomotherapy in patients with locally advanced pancreatic cancer. Radiother Oncol 2005;76(suppl 2):S165-S166
61. Berland LL, Silverman SG, Gore RM, et al. Managing incidental findings on abdominal CT: white paper of the ACR incidental findings committee. J Am Coll Radiol 2010;7:754-773
62. Tann M, Sandrasegaran K, Jennings SG, Skandarajah A, McHenry L, Schmidt CM. Positronemission tomography and computed tomography of cystic pancreatic masses. Clin Radiol 2007;62:745-751 (Pubitemid 46971644)
63. Pery C, Meurette G, Ansquer C, Frampas E, Regenet N. Role and limitations of (18) F-FDG positron emission tomography (PET) in the management of patients with pancreatic lesions. Gastroenterol Clin Biol 2010;34:465-474
64. Ford EC, Herman J, Yorke E, Wahl RL. (18) FFDG PET/CT for image-guided and intensitymodulated radiotherapy. J Nucl Med 2009;50:1655-1665
65. Wang Y, Chen ZM, Yaghmai V, et al. Diffusionweighted MR imaging in pancreatic endocrine tumors correlated with histopathologic characteristics. J Magn Reson Imaging 2011;33:1071-1079
66. Takakura K, Sumiyama K, Munakata K, et al. Clinical usefulness of diffusion-weighted MR imaging for detection of pancreatic cancer: comparison with enhanced multidetector-row CT. Abdom Imaging 2011;36:457-462
67. Park HS, Lee JM, Choi HK, Hong SH, Han JK, Choi BI. Preoperative evaluation of pancreatic cancer: comparison of gadolinium-enhanced dynamic MRI with MR cholangiopancreatography versus MDCT. J Magn Reson Imaging 2009;30:586-595
68. Strobel K, Heinrich S, Bhure U, et al. Contrastenhanced F-18-FDG PET/CT: 1-stop-shop imaging for assessing the resectability of pancreatic cancer. J Nucl Med 2008;49:1408-1413
69. [No authors listed]. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Gastrointestinal Tumor Study Group. Cancer 1987;59:2006-2010
70. Klinkenbijl JH, Jeekel J, Sahmoud T, et al. Adjuvant radiotherapy and 5-fluorouracil after curative resection of cancer of the pancreas and periampullary region: phase III trial of the EORTC Gastrointestinal Tract Cancer Cooperative Group. Ann Surg 1999;230:776-782
71. Neoptolemos JP, Dunn JA, Stocken DD, et al. Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 2001;358:1576-1585 (Pubitemid 33101907)
72. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med 2004;350:1200-1210 (Pubitemid 38339364)
73. Crane CH, Varadhachary G, Wolff RA, Pisters PW, Evans DB. The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancer. Best Pract Res Clin Gastroenterol 2006;20:365-382
74. Topkan E, Yavuz AA, Aydin M, Onal C, Yapar F, Yavuz MN. Comparison of CT and PET-CT based planning of radiation therapy in locally advanced pancreatic carcinoma. J Exp Clin Cancer Res 2008;27:41
75. 18Fluorodeoxyglucose PET is prognostic of progressionfree and overall survival in locally advanced pancreas cancer treated with stereotactic radiotherapy. Int J Radiat Oncol Biol Phys 2010;77:1420-1425
76. 18Fluorodeoxyglucose- positron emission tomography in the management of patients with suspected pancreatic cancer. Ann Surg 1999;229:729-737; discussion 737-738
77. Higashi T, Sakahara H, Torizuka T, et al. Evaluation of intraoperative radiation therapy for unresectable pancreatic cancer with FDG PET. J Nucl Med 1999;40:1424-1433 (Pubitemid 29428922)
78. Maisey NR, Webb A, Flux GD, et al. FDG-PET in the prediction of survival of patients with cancer of the pancreas: a pilot study. Br J Cancer 2000;83:287-293 (Pubitemid 30453565)
79. Yoshioka M, Sato T, Furuya T, et al. Role of positron emission tomography with 2-deoxy-2-[F-18] fluoro-d-glucose in evaluating the effects of arterial infusion chemotherapy and radiotherapy on pancreatic cancer. J Gastroenterol 2004;39:50-55 (Pubitemid 38208242)
80. Bang S, Chung HW, Park SW, et al. The clinical usefulness of 18-fluorodeoxyglucose positron emission tomography in the differential diagnosis, staging, and response evaluation after concurrent chemoradiotherapy for pancreatic cancer. J Clin Gastroenterol 2006;40:923-929 (Pubitemid 44690768)
81. Kuwatani M, Kawakami H, Eto K, et al. modalities for evaluating chemotherapeutic efficacy and survival time in patients with advanced pancreatic cancer: comparison between FDG-PET, CT, and serum tumor markers. Intern Med 2009;48:867-875
82. 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT). Abdom Imaging 2011;36:463-471
83. Hillner BE, Siegel BA, Liu D, et al. Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol 2008;26:2155-2161
84. Goh BK. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. Ann Surg 2006;243:709-710 (Pubitemid 44305599)
85. Heinrich S, Schafer M, Clavien PA. Positron emission tomography/computed tomography influences on the management of resectable pancreatic cancer and its cost-effectiveness. (letter) Ann Surg 2006;243:710
86. Langer A. A systematic review of PET and PET/CT in oncology: a way to personalize cancer treatment in a cost-effective manner? BMC Health Serv Res 2010;10:283